key: cord-0057914-5i22bdd2
authors: Chiarella, Sergio E.; Pabelick, Christina; Prakash, Y. S.
title: Sex Differences in the Coronavirus Disease 2019
date: 2021-03-19
journal: Sex-Based Differences in Lung Physiology
DOI: 10.1007/978-3-030-63549-7_16
sha: a97122344acda804b9e5ecc9cfc20aff377a57eb
doc_id: 57914
cord_uid: 5i22bdd2

There are profound sex differences in coronavirus disease 2019 (COVID-19) outcomes, with higher morbidity and mortality in males compared to females. The possible mechanisms implicated in this sex bias include the direct effects of sex hormones on the innate and adaptive immune systems, as well as the differential activity of immune-related genes in sex chromosomes. These male-female differences in COVID-19 outcomes highlight the need for sex-disaggregated data to elaborate effective public health policies and the importance of including biological sex as a key variable in future therapeutic and vaccine trials.

The ongoing coronavirus disease 2019 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a once-in-ageneration health crisis that continues to devastate communities across the globe. As of this writing, the Johns Hopkins Coronavirus Resource Center reported over 26 million confirmed COVID-19 cases and more than 880,000 deaths worldwide (Johns Hopkins University 2020). Importantly, demographic and clinical data gathered by multiple health agencies and governments have demonstrated profound sex differences in COVID-19 outcomes. Overall, the rate of SARS-CoV-2 infection is similar between the sexes. However, males have a higher risk of developing severe COVID-19 and dying when compared to females (Klein et al. 2020b) . In this chapter, we describe in detail the sex differences in COVID-19 outcomes and discuss the possible mechanisms behind them.

There is a significant sex bias in the immune response to viral infections, which is thought to be mostly the result of male-female differences in sex chromosomes and sex hormone milieu. Sex-specific immune responses to a diverse array of viral pathogens, including hantavirus, cytomegalovirus, human immunodeficiency virus, influenza virus, coxsackieviruses, herpes simplex virus, and hepatitis B virus, have been previously described (Bongen et al. 2019; Ghosh and Klein 2017; Piasecka et al. 2018; Schurz et al. 2019; vom Steeg and Klein 2016) . In addition, there are significant differences in the immune responses to viral vaccines of males and females (Klein and Flanagan 2016; Markle and Fish 2014) . In the case of coronavirus infections, there have been reports of sex differences during prior outbreaks. For instance, data from the Hong Kong Department of Health showed that, during the 2003 severe acute respiratory syndrome (SARS) outbreak, males had a higher case fatality rate (CFR) than females (21.9% versus 13.2%; p-value <0.0001) (Karlberg et al. 2004 ). Researchers in Singapore reported similar findings, with male sex being a significant univariate predictor of poor outcome in patients with SARS (odds ratio [OR], 3.1; 95% confidence interval [CI] 1. 64-5.87 ; p-value <0.001) (Leong et al. 2006) . There was also a male predominance during the Middle East respiratory syndrome (MERS) coronavirus epidemic, both in the number of deaths (74% of the fatalities were male) and the CFR (52% in males versus 23% in females) (Alghamdi et al. 2014 ).

The first reports of sex bias in COVID-19 came from China's Hubei province, where the pandemic is thought to have started. In a retrospective multicenter cohort study from Wuhan, Zhou and colleagues reported the outcomes of adult patients admitted to the hospital with COVID-19. Of the 191 individuals included in the study, 62% were male. Furthermore, of the 54 patients who died, 70% were male. The protective effect of female sex did not reach statistical significance (univariate logistic regression analysis showed an OR for female versus male sex, 0.61; 95% CI 0.31-1.2; p-value, 0.15), but a trend started to emerge . Similarly, in a subsequent retrospective case series from China, 274 patients with COVID-19 were studied. In this cohort, males represented 62% of the cases and 73% of the deaths, but the authors did not provide a statistical analysis of these sex differences (Chen et al. 2020a) .

In another case series from Wuhan, Jin and colleagues reported a similar rate of infection between sexes. Despite this, the mortality rate was 2.4 times higher in males compared to females (70.3% versus 29.7%; p-value ¼ 0.016), independent of age ). Survival analysis of 269 patients admitted to Tongji Hospital (Wuhan, China) with severe COVID-19 showed that male sex was associated with higher mortality (adjusted hazard ratio of 1.72; 95% CI 1.05-2.82; p-value ¼ 0.032) (Li et al. 2020b) . Other reports have shown significant sex differences in comorbidities and laboratory tests (neutrophil/lymphocyte ratio, C-reactive protein, aspartate aminotransferase, and serum creatinine) among 168 patients with severe COVID-19 (Meng et al. 2020) . Finally, a more recent meta-analysis by Li and colleagues, which included the demographic and clinical information of 1994 COVID-19 patients from 10 different publications, showed that males represent 60% of the cases (95% CI, 0.54-0.65) . Unfortunately, the authors did not present sex-disaggregated data on the CFR.

Other Asian countries have also reported significant sex differences in their COVID-19 outcomes. In a study from the Republic of Korea, data from 7755 individuals with confirmed SARS-CoV-2 infection were collected and analyzed. Interestingly, 62% of the cases were female individuals. Conversely, the CFR was higher in males (1.19% in men versus 0.52% in women) (Dudley and Lee 2020) . Iran has also reported on sexual dimorphism in COVID-19 outcomes, with one study showing higher mortality in males (OR, 1.45; 95% CI 1.08-1.96; p-value, 0.01) (Nikpouraghdam et al. 2020) .

Sex-disaggregated data from Europe has also shown significant male predominance in COVID-19 morbidity and mortality, which suggests these findings are not specific to Asian populations. In this regard, one of the first reports came from Lombardy, Italy. In their retrospective case series, Grasselli and colleagues found that 82% of 1591 consecutive patients with confirmed COVID-19 requiring admission to the intensive care unit (ICU) were males (Grasselli et al. 2020) . A subsequent European study described the clinical and laboratory differences between cohorts of bacterial community-acquired pneumonia (CAP) and SARS-CoV-2 pneumonia. In this study, it was noted that 89.3% of the patients who developed severe respiratory failure due to SARS-CoV-2 were males. This is in stark contrast with data from their bacterial CAP cohort, in which only 48.2% of the patients who developed severe respiratory failure were males (Giamarellos-Bourboulis et al. 2020 ). In another Italian study evaluating the radiological abnormalities in patients infected with SARS-CoV-2, it was noted that males between the ages of 50 and 79 had a significantly worse radiographic score when compared to their female counterparts (Borghesi et al. 2020) . Finally, in a study involving COVID-19 data from six European countries (Italy, Spain, Germany, Switzerland, Belgium, and Norway), the authors found a greater rate of SARS-CoV-2 infection among 10-to 50-year-old women, when compared to men of the same age. Nevertheless, among all age groups, males had a higher fatality rate when compared to females (Marina and Lorenzo 2020) .

In the United States, most of the states have made public sex-disaggregated data on COVID-19 morbidity and mortality. In an article published in June of 2020, Klein and colleagues reported that data from 16 states suggests a female bias in SARS-CoV-2 infections (1 to 0.9/0.8 male to female ratio). In the states where sex-disaggregated information regarding COVID-19 deaths has been made available, the data shows that men are twice as likely to die from COVID-19 when compared to women (Klein et al. 2020b) . This is consistent with data from the Chinese and European studies discussed above. In a case series of 5700 patients hospitalized with COVID-19 from 12 hospitals in the state of New York, the authors showed that 60.3% of them were male. Furthermore, when analyzing the patient's discharge disposition at 10-year age intervals, the data showed that from 20 years onward, a higher proportion of males died. As an example, in the age interval of 50-59 years, 12.2% of males died compared to only 6.9% of females (Richardson et al. 2020) .

A more recent study of moderate COVID-19 cases dissected the sex differences in the immune response to SARS-CoV-2. In this cohort from Yale University, males had higher plasma levels of interleukin (IL)-8, IL-18, and chemokine ligand 5 (CCL5), while females had higher CD4 and CD8 T cell activation (Takahashi et al. 2020) . Intriguingly, a recent study from Johns Hopkins University using convalescent plasma showed higher microneutralization and IgG responses to SARS-CoV-2 in males compared to females. The authors also reported that a greater IgG response correlated with worse COVID-19 outcomes (Klein et al. 2020a ). These findings warrant further evaluation, as it seemingly contradicts prior studies showing that females have a more robust adaptive immune system than males (Klein and Flanagan 2016) .

In a more global study that analyzed data from 38 countries, Scully and colleagues found that, on average, males had a 1.7 higher CFR compared to females (7.3 versus 5.4; p-value <0.0001). When analyzing age-disaggregated data, males 30 years and older had a consistently higher risk of dying from COVID-19 (Scully et al. 2020) . The authors obtained some of the information from the Global Health 50/50 COVID-19 data tracker, a notable source of sex-disaggregated data during the COVID-19 pandemic (Global Health 2020).

Interestingly, these male-female differences in coronavirus infections have also been noted in preclinical murine studies. In a pivotal study from 2017, investigators infected age-matched B6 mice from both sexes with different doses of mouseadapted SARS-CoV (MA15). When infecting mice with 5000 plaque-forming units (PFUs) of MA15, 90% of male mice died versus only 20% of female mice. Increasing the infection dose to 10,000 PFUs resulted in the death of all male mice, while 40% of female mice survived. These sex differences in MA15-induced mortality were more pronounced with increasing age of the mice (Channappanavar et al. 2017) .

In summary, there is a male predominance in almost every country reporting sex-disaggregated data on COVID-19 outcomes. In the following section, we will explore the possible mechanisms involved in this sex bias. These include differences in the sex hormone milieu and the copy numbers of X-linked genes relevant to the immune response against SARS-CoV-2.

X chromosome inactivation and female mosaicism (Lyon 1961) are particularly relevant to the sex bias observed in COVID-19 outcomes. Early in development, one of the female X chromosomes becomes transcriptionally inactive. This process, termed X chromosome inactivation, is random, and the result is two populations of somatic cells that differ in their active X chromosome, i.e., female mosaicism (Machiela et al. 2016) . Importantly, the X chromosome has a high number of immune-related genes, including some involved in cytokine and toll-like receptor (TLR) signaling (IL1RAPL1, IL1RAPL2, IL2RG, IL13RA1, IL13RA2, CXCR3,  TLR7 , and TLR8), NF-κB and MAPK signaling (IKBKG, NKRF, NKAP, and MKP4), and apoptosis (XIAP, AIFM1, and IGBP1) (Spolarics et al. 2017 ). X chromosome inactivation and female mosaicism can directly impact immune function and a patient's response to viral infections and vaccines. As an example, Fink and colleagues have demonstrated that epigenetic regulation of TLR7 is implicated in the sex differences observed in vaccine-induced antibody responses (Fink et al. 2018) . The presence of the Y chromosome in males can also significantly impact immunity. For instance, genetic variation in the Y chromosome has been shown to impact influenza-induced lung inflammation via the activation of IL-17-producing γδ T cells (Krementsov et al. 2017) . Overall, male-female differences in sex chromosomes can significantly impact the immune response to viral infections, which is highly relevant in the setting of the COVID-19 pandemic.

The impact of male-female chromosomal differences on COVID-19 outcomes is also highlighted by the gene encoding the human angiotensin-converting enzyme 2 (ACE2). ACE2 serves as the receptor for the spike (S) protein of SARS-CoV and SARS-CoV-2 (Chen et al. 2020b; Ge et al. 2013; Hoffmann et al. 2020; Li et al. 2003 Li et al. , 2005a and plays a pivotal role in their infectivity. Such is the significance of ACE2 that it is being considered as a potential therapeutic target for COVID-19 . Importantly, although the ACE2 gene is located in the X chromosome, it can escape X inactivation and be expressed from both the active and inactive X chromosome (Carrel and Willard 2005) . This has been shown to lead to sex differences in ACE2 gene expression (Gemmati et al. 2020; Li et al. 2020c; Tukiainen et al. 2017) , which have potential consequences for the vulnerability to SARS-CoV-2.

Sex differences in TLR signaling and the interferon (IFN) response might also play a role in the sex bias observed in COVID-19. Several TLRs are encoded in the X chromosome (Libert et al. 2010 ) and have been implicated in sex-specific immune responses to viral infections (Meier et al. 2009 ). TLR7 is able to recognize SARS-CoV-specific GU-rich single-stranded RNA (ssRNA), activating downstream signaling events which lead to the upregulation of pro-inflammatory cytokines such as the tumor necrosis factor-alpha (TNF-α), interleukin IL-6, and IL-12 (Cervantes- Barragan et al. 2007; Li et al. 2016 ). As mentioned above, the gene for TLR7 is located in the X chromosome. As with the case of the ACE2 gene, the TLR7 gene can also avoid X inactivation (Souyris et al. 2018) . TLR4 signaling genes, such as IL-1 receptor-associated kinase (IRAK) 1, have also been implicated in sex-specific susceptibility to infections (O'Driscoll et al. 2017 ). In addition, sexual dimorphism in the response to TLR3 activation has been reported (Chavez-Valdez et al. 2019). Interestingly TLR3 signaling through TRIF adaptor protein has been shown to protect mice from a lethal SARS-CoV disease (Totura et al. 2015) . Finally, an abnormal interferon response has been associated with COVID-19, with low levels of type I and II IFNs (Blanco-Melo et al. 2020). There have been reports of sex differences in IFN production from plasmacytoid dendritic cells (pDCs), with higher levels in females compared to males (Berghofer et al. 2006; Meier et al. 2009 ).

Finally, X-linked genetic variability and mosaicism might also influence the cytokine storm reported in severe cases of COVID-19. This cytokine storm is characterized by elevated plasma levels of IL-2, IL-6, IL-7, granulocyte-colony stimulating factor, IFN-γ-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1α, and TNF-α Mehta et al. 2020) . Furthermore, IL-6 levels have been shown to be a good predictor of severity and death in patients with COVID-19 (Grifoni et al. 2020) . Interestingly, females express lower levels of IL-6 in response to viral infections (Conti and Younes 2020).

The diverse effects of estrogen on the immune system have been described in prior publications, and the reader is referred to other excellent reviews on this topic (Han et al. 2018; Straub 2007; Townsend et al. 2012) . Notably, estrogen can regulate viral replication in nasal epithelial cells. Peretz and colleagues showed that 17β-estradiol, via ERβ, decreased the viral titer in human nasal epithelial cells from female donors, but not in the cells from male donors (Peretz et al. 2016 ). Estrogen could potentially have similar effects during a SARS-CoV-2 infection, limiting viral replication.

Estrogen can also regulate the expression of SARS-CoV-2 viral entry receptors, such as ACE2 and the transmembrane protease, serine 2 (TMPRSS2). As mentioned above, SARS-CoV-2 uses membrane-bound ACE2 (mACE2) as a cellular receptor, and TMPRSS2 is required for S protein priming (Hoffmann et al. 2020 ). It has been hypothesized that sex differences in lung mACE2 might be directly implicated in the sex bias of COVID-19 (Majdic 2020) . The A disintegrin and metalloproteinase 17 (ADAM-17) enzyme can cleave mACE2, shedding soluble ACE2 (sACE2) (Heurich et al. 2014; Haga et al. 2008; Patel et al. 2014 ). Interestingly, Sward and colleagues have reported that females age 15 and older have lower levels of sACE2 when compared to age-matched males (Sward et al. 2020) . Furthermore, the serum activity of ACE2 is higher in older women (age 55 or older) when compared to younger women (Gebhard et al. 2020) . The authors of this last study speculate that this increase in ACE2 activity with age might be related to changes in sex hormones, particularly estrogen.

In the bronchial epithelium, ACE2 is primarily expressed in transient secretory cells (Lukassen et al. 2020) . Our group has shown that estrogen can regulate the expression of ACE2 in differentiated airway epithelial cells. We treated normal human bronchial epithelial (NHBE) cells with estrogen or vehicle during their differentiation process in air-liquid interface. When compared to control, estrogen treatment led to a significant reduction in ACE2 (Stelzig et al. 2020 ). Other researchers have also identified estrogen effects on ACE2. Liu and colleagues have shown that ACE2 activity and enzyme velocity is higher in male mice, when compared to their female counterparts. A series of elegant experiments by this group using XX and XY gonadal females and XX and XY gonadal males determined that these sex differences are estrogen-dependent and sex chromosome-independent (Liu et al. 2010 ). In addition, estrogen treatment of oophorectomized rats led to a reduction in cardiac ACE2 expression . Interestingly, deletion of estrogen-related receptor alpha (ERRα) also leads to an upregulation of ACE2 (Tremblay et al. 2010) .

Although less studied, estrogen has also been shown to have an effect on the TMPRSS2:v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2-ERG) expression in malignant prostate cells. Treatment with an ERβ agonist led to a decrease in the expression of TMPRSS2-ERG, while treatment with an ERα agonist had the opposite effect (Setlur et al. 2008) . Of note, in our studies using differentiated airway epithelial cells, we found no significant effect of estrogen on the expression of TMPRSS2 (Stelzig et al. 2020) .

As mentioned previously, the sex-specific interferon response to SARS-CoV-2 might contribute to the sex bias in COVID-19. The pDC TLR-mediated type I interferon response to viruses is higher in females compared to males (Berghofer et al. 2006; Meier et al. 2009 ). By targeting ERα in pDCs, estrogen can promote this interferon response (Seillet et al. 2012) . Conversely, inhibiting ER signaling during pDC development leads to a diminished production of interferon (Laffont et al. 2014) . Finally, genetic deletion of ERα in mice results in a reduction in the expression of IRF5 and the downstream interferon response (Griesbeck et al. 2015) .

The protective effects of estrogen signaling in the context of coronavirus infections have also been shown in murine studies. In a seminal paper, Channappanavar and colleagues showed that oophorectomized female mice had a higher mortality when infected with MA15, the mouse-adapted SARS-CoV. Furthermore, treatment with an estrogen receptor antagonist increased the susceptibility of female mice to this viral infection, while treatment with tamoxifen decreased it (Channappanavar et al. 2017) .

Progesterone can also regulate several components of the innate and adaptive immune system. By interacting with progesterone receptors in macrophages, dendritic cells, natural killer cells, T cells, and B cells, progesterone can affect mucosal immunity in the respiratory tract . Relevant to the COVID-19 pandemic, progesterone has been shown to regulate lung inflammation and promote tissue repair after a viral infection by increasing the production of epidermal growth factor amphiregulin (Hall et al. 2016) . In a murine model of influenza A virus infection, progesterone had a protective effect on naïve female mice, but not in the mice that had undergone a prior viral challenge ).

The effects of androgen signaling on the innate and adaptive immune system are diverse and have been previously reviewed (Gubbels Bupp and Jorgensen 2018; Kissick et al. 2014; Lai et al. 2012; Trigunaite et al. 2015) . So far, it is unclear if low or high androgen levels contribute to severe outcomes in COVID-19. Some have shown that elevated testosterone levels correlate with low antibody levels to vaccines (Furman et al. 2014) . Others hypothesize that SARS-CoV-2 infection might trigger acute male hypogonadism with low androgen levels, which may contribute to increased COVID-19 morbidity and mortality (Channappanavar et al. 2017; Salonia et al. 2020) . As an example, Rastrelli and colleagues have shown that, in males with SARS-CoV-2 pneumonia, low total testosterone (less than 5 nmol/L) and low calculated free testosterone (less than 100 pmol/L) are associated with higher rates of ICU transfer and death (Rastrelli et al. 2020) . Interestingly, human studies have shown that testosterone can upregulate IL-1 and downregulate IL-1β IL-6, and TNF-α, leading to a suppression of inflammation (Mohamad et al. 2019; Pozzilli and Lenzi 2020) . Future studies investigating the effects of androgen levels on COVID-19 should consider the timing of the androgen measurement in the course of the SARS-CoV-2 infection (Strope et al. 2020) .

Another mechanism by which testosterone might predispose males to worse COVID-19 outcomes is by regulating the expression of TMPRSS2 (Giagulli et al. 2020; Stopsack et al. 2020 ). In the context of coronavirus infections, TMPRSS2 is not only a key element for S protein activation and virus-cell fusion but can also decrease viral recognition by neutralizing antibodies (Glowacka et al. 2011 ). TMPRSS2 is highly expressed in urogenital organs, such as the prostate (Chakravarty et al. 2020) . Therefore, it is not surprising that testosterone regulation of TMPRSS2 expression was first identified in studies of prostate cancer biology. In prostate cancer cells, the TMPRSS2 gene is commonly fused to ETS transcription factors, such as ERG or ETV1. Androgen-responsive elements within TMPRSS2 mediate the increased expression of ERG or ETV1, which in turn has important prognostic implications for prostate cancer patients (Fernandez et al. 2015; Hagglof et al. 2014; Lucas et al. 2014; Tomlins et al. 2005) . Importantly, androgen-induced upregulation of TMPRSS2 has also been reported in a human lung adenocarcinomaderived (A549) cell line (Mikkonen et al. 2010 ).

Given the marked sex bias in COVID-19 outcomes and multiple preclinical studies demonstrating the ability of sex hormones to regulate different aspects of SARS-CoV-2 infectivity, several clinical trials targeting sex steroid signaling have been initiated across the globe. These clinical studies have been summarized in Future clinical studies should also investigate the effects of estrogen replacement therapy and androgen deprivation therapy (ADT) on COVID-19 outcomes. Italian researchers have reported a lower risk of SARS-CoV-2 infection in patients with prostate cancer receiving ADT than those not receiving ADT (OR, 4.05; 95% CI (Montopoli et al. 2020) . Others have shown that abiraterone, an androgen biosynthesis inhibitor, has in vitro anti-SARS-CoV-2 activity, reducing the virus-induced cytopathic effects by approximately 70% (Yuan et al. 2020 ).

The study of individuals with COVID-19 who have comorbidities such as polycystic ovarian syndrome or androgenetic alopecia (AGA; also known as male pattern hair loss) could also shed light on the effects of sex steroid signaling on this disease. For instance, Goren and colleagues noted that 71% of Caucasian males (n ¼ 41) who were admitted with bilateral SARS-CoV-2 pneumonia had clinically significant AGA . A subsequent study by the same research group confirmed this observation, finding that 67% of patients (n ¼ 175) with COVID-19 had AGA . The authors speculate the increased androgen sensitivity might predispose patients with AGA to more severe forms of COVID-19.

In addition to the efforts to conduct clinical trials specifically targeting steroid signaling pathways, it is of paramount importance to include sex as a biological variable in all other COVID-19 therapeutic studies. Medications can have sex-specific pharmacogenomic, pharmacokinetic, and pharmacodynamics properties (Bartz et al. 2020; Franconi and Campesi 2014) . Furthermore, multiple studies with immunotherapies (such as antiviral agents, convalescent plasma, and vaccines) have already demonstrated the importance of biologic sex when studying drug efficacy (Grassadonia et al. 2018; Jawaheer et al. 2012; Klein and Morgan 2020) .

Preclinical studies involving mice have shown that serum from female mice is better at protecting naïve mice than serum from male mice (Fink et al. 2018 ). In addition, it is important to consider the sex differences in adverse drug reactions, since they tend to be more prevalent in female patients (Bischof et al. 2020) . Finally, biological sex should even be a key variable in studies addressing mechanical ventilation strategies, as male-female differences in lung volumes could impact the COVID-19 outcomes of mechanically ventilated patients (Han et al. 2018 ).

Sex is a biological variable, while gender is defined as the socially constructed roles, behaviors, and expressions of men and women. Although not the primary focus of this chapter, gender can also contribute to differences in COVID-19 outcomes. For example, there are marked gender differences in smoking habits among certain populations. In China, 288 million men smoke versus only 12.6 million women (Cai 2020) . Importantly, smoking has been shown to be a risk factor for adverse outcomes in COVID-19, which may disproportionally affect men (Vardavas and Nikitara 2020) . There are also significant gender differences in comorbidities (Sharma et al. 2020) . Importantly, the CFR for COVID-19 is elevated for patients with cardiovascular disease (10.5%), diabetes (7.3%), chronic pulmonary disease (6.3%), hypertension (6%), and cancer (5.6%) (Wu and McGoogan 2020) . In general, these comorbidities tend to be more prevalent in men.

In certain communities, women are the predominant caregivers at home and in healthcare settings. This places them at an increased risk of becoming infected with SARS-CoV-2 (Wenham et al. 2020) . Women are also at increased risk for psychiatric disorders ) and social isolation (Senst et al. 2016 ) during the pandemic, which might result in worse outcomes. Even the gendered behavior of handwashing, which is lower in men, can have an impact on the rate of SARS-CoV-2 infections (Gebhard et al. 2020) . Overall, COVID-19 will bring to the frontline several structural gender health disparities that will need to be addressed in order to effectively mitigate the pandemic (Spagnolo et al. 2020 ).

There are profound sex differences in the vulnerability to COVID-19. The mechanisms involved in this sex bias are still unclear, but experts in the field agree that differences in sex chromosomes and the direct action of sex steroids are likely contributing. Further mechanistic studies are required to address this knowledge gap. Biological sex is also an important variable to incorporate into future COVID-19 therapeutic and vaccine trials. Finally, the authors believe that sex-disaggregated data and sex-specific interventions are crucial to establishing efficient public health policies in order to manage and mitigate the adverse outcomes of the COVID-19 pandemic.

The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health

Clinical advances in sex-and gender-informed medicine to improve the health of all: a review

TLR7 ligands induce higher IFN-alpha production in females

Clinical trials for COVID-19 should include sex as a variable

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Sex differences in the blood transcriptome identify robust changes in immune cell proportions with aging and influenza infection

Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients

Sex difference and smoking predisposition in patients with COVID-19

X-inactivation profile reveals extensive variability in X-linked gene expression in females

Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon

Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer

Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection

Evidence for sexual dimorphism in the response to TLR3 activation in the developing neonatal mouse brain: a pilot study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Structure analysis of the receptor binding of 2019-nCoV

Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection

Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea

Dual targeting of the androgen receptor and hypoxia-inducible factor 1alpha pathways synergistically inhibits castration-resistant prostate cancer cells

Biological sex affects vaccine efficacy and protection against influenza in mice

Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women

Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

Impact of sex and gender on COVID-19 outcomes in Europe

COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males?

Sex drives dimorphic immune responses to viral infections

Worse progression of COVID-19 in men: is testosterone a key factor? Andrology

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

50 (2020) Sex, gender and COVID-19: overview and resources

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain -a potential clue to the role of androgens in COVID-19 severity

Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced Cancer: a systematic review and meta-analysis of phase III randomized clinical trials

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region

Sex differences in Plasmacytoid dendritic cell levels of IRF5 drive higher IFN-alpha production in women

Interleukin-6 as prognosticator in patients with COVID-19

Androgen-induced immunosuppression

Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry

TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers

Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites

Progesterone-based therapy protects against influenza by promoting lung repair and recovery in females

Progesterone-based contraceptives reduce adaptive immune responses and protection against sequential influenza a virus infections

Female sex and gender in lung/sleep health and disease. Increased understanding of basic biological, pathophysiological, and behavioral mechanisms leading to better health for female patients with lung disease

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Clinical features of patients infected with 2019 novel coronavirus in

Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients

Gender differences in patients with COVID-19: focus on severity and mortality

Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?

Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation

Sex differences in immune responses

The impact of sex and gender on immunotherapy outcomes

Tobian A (2020a) Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Biological sex impacts COVID-19 outcomes

Genetic variation in chromosome Y regulates susceptibility to influenza a virus infection

X-chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-alpha production of plasmacytoid dendritic cells from women

Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice

SARS in Singapore--predictors of disease severity

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked Polyubiquitination of TRAF3 and TRAF6

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Molecular mechanisms of sex bias differences in COVID-19 mortality

The X chromosome in immune functions: when a chromosome makes the difference

Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent

Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: gender differences matter

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

Gene action in the X-chromosome of the mouse (Mus musculus L.)

Could sex/gender differences in ACE2 expression in the lungs contribute to the large gender disparity in the morbidity and mortality of patients infected with the SARS-CoV-2 virus?

Gender and age effects on the rates of infection and deaths in individuals with confirmed SARS-CoV-2 infection in six european countries

SeXX matters in immunity

Hlh Across Speciality Collaboration UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression

Sex differences in the toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1

Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients

Androgen receptor and androgendependent gene expression in lung

The relationship between circulating testosterone and inflammatory cytokines in men

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study

Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: a single center study

Expression of X-linked toll-like receptor 4 signaling genes in female vs. male neonates

Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ ADAM-17: a positive feedback mechanism in the RAS

Estrogenic compounds reduce influenza a virus replication in primary human nasal epithelial cells derived from female, but not male, donors

Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges

Commentary: testosterone, a key hormone in the context of COVID-19 pandemic

Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area

SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): a multidimensional research project

The X chromosome and sex-specific effects in infectious disease susceptibility

Considering how biological sex impacts immune responses and COVID-19 outcomes

The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling

Sexually dimorphic neuronal responses to social isolation. elife 5:e18726

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer

Sex differences in mortality from COVID-19 pandemic: are men vulnerable and women protected? JACC Case Rep 2:1407

TLR7 escapes X chromosome inactivation in immune cells

Sex and gender differences in health: what the COVID-19 pandemic can teach us

Inherent X-linked genetic variability and cellular mosaicism unique to females contribute to sex-related differences in the innate immune response

Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells

Kantoff PW (2020) TMPRSS2 and COVID-19: serendipity or opportunity for intervention?

The complex role of estrogens in inflammation

Are sex discordant outcomes in COVID-19 related to sex hormones?

Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients

Age and sex differences in soluble ACE2 may give insights for COVID-19

Sex differences in immune responses that underlie COVID-19 disease outcomes

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer

Tolllike receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection

Sex differences and sex steroids in lung health and disease

Physiological genomics identifies estrogen-related receptor alpha as a regulator of renal sodium and potassium homeostasis and the renin-angiotensin pathway

Suppressive effects of androgens on the immune system

Coordinating Center -Analysis Working G, Statistical Methods groups-Analysis Working G, Enhancing Gg, Fund NIHC, Nih/Nci, Nih/Nhgri, Nih/Nimh, Nih/Nida, Biospecimen Collection Source Site N, Biospecimen Collection Source Site R, Biospecimen Core Resource V, Brain Bank Repository-University of Miami Brain Endowment B, Leidos Biomedical-Project M, Study E, Genome Browser Data I, Visualization EBI, Genome Browser Data I, Visualization-Ucsc Genomics Institute UoCSC

COVID-19 and smoking: a systematic review of the evidence

SeXX matters in infectious disease pathogenesis

Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the "Gabrin sign

Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats

COVID-19: the gendered impacts of the outbreak

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention

Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Acknowledgments This book chapter was supported by NIH grants K08 AI141765 (SEC), R01 HL142061 (CMP, YSP), and R01 HL088029, R01 HL056470 (YSP).